




PHARMACEUTICAL 2020

INTERCEPT PHARMACEUTICALS
INC.
Rank 269 of 358





PHARMACEUTICAL 2020

INTERCEPT PHARMACEUTICALS INC. Rank 269 of 358



The relative strengths and weaknesses of INTERCEPT PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTERCEPT PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 23% points. The greatest weakness of INTERCEPT PHARMACEUTICALS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 137% points.

The company's Economic Capital Ratio, given in the ranking table, is -35%, being 71% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	721,315
Cost of Goods Sold	4,212
Intangible Assets	0
Liabilities, Current	162,005
Liabilities, Non-Current	541,325
Other Assets	28,369
Other Compr. Net Income	1,122
Other Expenses	0
Other Liabilities	0
Other Net Income	-32,254
Other Revenues	252,002
Property and Equipment	5,202
Research and Development	242,799
Selling, General and Administrative Expense	317,418

Output Variable	Value in 1000 USD
Assets	754,886
Liabilities	703,330
Expenses	564,429
Revenues	252,002
Stockholders Equity	51,556
Net Income	-344,681
Comprehensive Net Income	-344,120
Economic Capital Ratio	-35%